Globus Medical, Inc. (NYSE:GMED) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Globus Medical, Inc. (NYSE:GMED) have earned a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $99.00.

A number of research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Globus Medical in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. TD Cowen initiated coverage on shares of Globus Medical in a research note on Monday. They issued a “buy” rating and a $110.00 price target for the company. Morgan Stanley boosted their price objective on shares of Globus Medical from $70.00 to $100.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, BTIG Research restated a “neutral” rating on shares of Globus Medical in a report on Tuesday, December 30th.

Insider Activity

In related news, CFO Kyle Kline sold 18,542 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $90.00, for a total transaction of $1,668,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ann D. Rhoads sold 8,000 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $81.00, for a total value of $648,000.00. Following the completion of the transaction, the director directly owned 17,384 shares in the company, valued at approximately $1,408,104. This represents a 31.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 91,636 shares of company stock worth $7,984,583. Insiders own 18.54% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Several institutional investors have recently made changes to their positions in the business. Advisory Services Network LLC purchased a new position in shares of Globus Medical in the third quarter worth approximately $26,000. EverSource Wealth Advisors LLC raised its position in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the period. Advisors Asset Management Inc. purchased a new position in shares of Globus Medical during the 2nd quarter worth $28,000. First Horizon Corp bought a new stake in shares of Globus Medical during the 3rd quarter valued at $31,000. Finally, Parallel Advisors LLC grew its position in shares of Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares during the period. Institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Performance

Shares of NYSE GMED opened at $92.90 on Thursday. The firm’s 50 day moving average price is $89.49 and its 200-day moving average price is $70.70. Globus Medical has a 52-week low of $51.79 and a 52-week high of $101.40. The company has a market cap of $12.43 billion, a PE ratio of 29.97, a P/E/G ratio of 1.37 and a beta of 1.06.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, November 6th. The medical device company reported $1.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.39. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The company had revenue of $769.05 million during the quarter, compared to analyst estimates of $734.58 million. During the same period in the previous year, the business earned $0.83 EPS. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. On average, analysts forecast that Globus Medical will post 3.44 earnings per share for the current fiscal year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.